{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106932","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.223821+00:00","generated_at":"2026-05-17T14:50:35.943286+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Coya Therapeutics Q2 2025 net loss $6.1M; cash $29.8M; FDA decision on COYA 302 ALS IND by Aug 29","bullets":["Net loss $6.1M vs $2.9M in Q2 2024; collaboration revenue fell to $0.2M from $3.4M.","Cash and equivalents $29.8M as of June 30, 2025.","R&D expenses $3.7M (down $0.9M YoY); G&A $2.9M (up $0.8M YoY).","FDA decision on IND for COYA 302 in ALS expected by August 29, 2025; upon acceptance, DRL milestone payment of $8.4M.","Additional catalysts: top-line data from FTD trial, IND for FTD by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106932","json":"https://secwatch.observer/filing/0000950170-25-106932.json","markdown":"https://secwatch.observer/filing/0000950170-25-106932.md","text":"https://secwatch.observer/filing/0000950170-25-106932.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000095017025106932/0000950170-25-106932-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000095017025106932/coya-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:50:35.943286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}